Table 1.
Demographic and clinical characteristics by convergence insufficiency (CI) status.
|
All participants (n = 24) |
Symptomatic CI (n = 17) |
Asymptomatic CI (n = 7) |
p-value | |
|---|---|---|---|---|
| Age (years) | 71.3 (5.6) | 71 (6.2) | 72 (4.0) | 0.70 |
| Sex (% female) | 41.7% | 47.1% | 28.6% | 0.40 |
| Education (years) | 15.8 (2.4) | 15.5 (2.3) | 16.3 (2.5) | 0.49 |
| Neurological Diagnosis (n) | ||||
| PD | 18 | 14 | 4 | |
| PSP | 5 | 3 | 2 | |
| MSA | 1 | 0 | 1 | |
| Disease duration (years) | 9.1 (8.6) | 10.2 (9.5) | 6.4 (5.7) | 0.34 |
| UPDRS Part III score | 29 (11.7) | 27.8 (11.4) | 32.5 (12.6) | 0.40 |
| Presence of dyskinesia (% with) | 16.7% | 23.5% | 0% | 0.19 |
| Medication use (% taking) | ||||
| Amantadine | 16.7% | 23.5% | 0% | 0.19 |
| MAO-B Inhibitor | 37.5% | 41.2% | 28.6% | 0.69 |
| Trihexiphenidyl | 4.2% | 5.9% | 0% | 0.54 |
| Donepezil | 16.7% | 11.8% | 28.6% | 0.26 |
| Presence of DBS (% with) | 20.8% | 23.5% | 14.3% | 0.70 |
| NPC (in cm) | 15.7 (5.1) | 16.4 (5.5) | 14.1 (3.9) | 0.35 |
| Subjective cognitive complaints (% reporting) | 75% | 76.5% | 71.4% | 0.80 |
| Cognitive impairment (% with) | 54.1% | 47% | 71.4% | 0.23 |
| Total SAGE score (max 22) | 16.5 (5.0) | 17.0 (1.1) | 15.4 (6.0) | 0.50 |
Data presented as mean (SD) unless otherwise noted. CI, convergence insufficiency; PD, Parkinson's disease; PSP, Progressive supranuclear palsy; MSA, Multiple system atrophy; UPDRS, Unified Parkinson's Disease Rating Scale; DBS, Deep brain stimulation; NPC, near point of convergence; SAGE, Self-Administered Gerocognitive Exam.